BMRN
Biomarin Pharmaceutical Inc
Biomarin Pharmaceutical Inc historical holders
total: 4
Dodge & Cox Stock Fund Biomarin Pharmaceutical Inc transactions over time
- Total transactions:
- 13
- New positions:
- 1
- Added:
- 9
- Reduced:
- 3
- Held since:
- 2019 Q4
- Held for:
- 26 quarters
- Latest activity:
- 2024 Q4
Dodge & Cox Stock Fund has been an institutional investor in Biomarin Pharmaceutical Inc (BMRN) since 2019 Q4. According to 2026 Q1 report, Dodge & Cox Stock Fund holds 9,769,625 shares with a market value of roughly $551.89M representing 0.48% of their equity portfolio. The fund/company first acquired BMRN in 2019 Q4, initially purchasing about 2.96M shares. Since the initial investment, Dodge & Cox Stock Fund has made 12 more transactions in this position.
Does Dodge & Cox Stock Fund still hold BMRN?
Yes, Dodge & Cox Stock Fund continues to hold Biomarin Pharmaceutical Inc (BMRN). According to their 2026 Q1 report, they maintain a position of 9,769,625 shares valued at approximately $551.89M, representing 0.48% of their equity portfolio.
When did Dodge & Cox Stock Fund first invest in BMRN?
Dodge & Cox Stock Fund first invested in Biomarin Pharmaceutical Inc (BMRN) in 2019 Q4 at the reported quarter-end price of $84.55 per share, acquiring 2,956,325 shares in their initial purchase.
What is Dodge & Cox Stock Fund's average cost basis for BMRN?
Based on historical transaction data, Dodge & Cox Stock Fund's estimated cost basis for Biomarin Pharmaceutical Inc (BMRN) is approximately $80.46 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $80.46
- Weighted AVG sell price:
- $98.00
BMRN transactions history by Dodge & Cox Stock Fund
13 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q4
|
0.58%
|
9,769,625
|
$65.73
|
$642,157,451
|
+9.60% (+855,600)
|
+0.05%
|
|
2023 Q3
|
0.85%
|
8,914,025
|
$88.48
|
$788,712,932
|
+0.53% (+47,000)
|
+0%
|
|
2023 Q2
|
0.83%
|
8,867,025
|
$86.68
|
$768,593,727
|
+0.36% (+32,200)
|
+0%
|
|
2022 Q4
|
1.04%
|
8,834,825
|
$103.49
|
$914,316,039
|
-1.89% (-170,400)
|
-0.02%
|
|
2022 Q3
|
0.97%
|
9,005,225
|
$84.77
|
$763,372,923
|
+0.21% (+18,500)
|
+0%
|
|
2021 Q3
|
0.76%
|
8,986,725
|
$77.29
|
$694,583,975
|
+6.08% (+515,300)
|
+0.04%
|
|
2021 Q2
|
0.79%
|
8,471,425
|
$83.44
|
$706,855,702
|
+26.41% (+1,770,142)
|
+0.17%
|
|
2021 Q1
|
0.62%
|
6,701,283
|
$75.51
|
$506,013,879
|
+21.31% (+1,177,158)
|
+0.11%
|
|
2020 Q4
|
0.69%
|
$87.69
|
+33.33% (+1,380,965)
|
|||
|
2020 Q3
|
0.52%
|
$76.08
|
+78.10% (+1,816,835)
|
|||
|
2020 Q2
|
0.48%
|
$123.34
|
-7.73% (-195,000)
|
|||
|
2020 Q1
|
0.41%
|
$84.50
|
-14.71% (-435,000)
|
|||
|
2019 Q4
|
0.34%
|
$84.55
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.